Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...